Clinical Trial Update: A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ramucirumab in Japanese patients with metastatic gastric or gastroesophageal junction cancer has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-22